Related Experiment Video
Updated: Jun 13, 2026
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Biomarkers in colorectal cancer
B Markman1, V Rodríguez-Freixinos, J Tabernero
1Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Summary
New systemic therapies improve colorectal cancer outcomes, but patient responses vary. Biomarker research is crucial for optimizing treatment efficacy and reducing toxicity in cancer care.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacogenomics
Background:
- Systemic therapies for colorectal cancer have advanced, improving patient outcomes.
- However, a significant number of patients do not benefit or experience severe side effects.
- Optimizing current treatments and discovering new agents remain critical challenges.
Purpose of the Study:
- To highlight the need for novel anticancer agents for colorectal cancer.
- To emphasize the importance of optimizing the use of existing treatments.
- To underscore the potential of biomarkers in improving colorectal cancer treatment.
Main Methods:
- Review of recent advancements in systemic therapies for colorectal cancer.
- Analysis of treatment response variability and toxicity profiles.
- Exploration of the role of biomarkers in cancer research and clinical application.
Main Results:
- Despite therapeutic progress, substantial patient populations face treatment challenges.
- Biomarker research offers a promising avenue for personalized cancer therapy.
- Validated biomarkers can enhance understanding of colorectal cancer biology.
Conclusions:
- Continued research into novel therapies and treatment optimization is essential for colorectal cancer management.
- Biomarkers are key to improving treatment efficiency and patient outcomes.
- Integrating biomarker data into clinical practice has the potential to revolutionize colorectal cancer care.
